Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro

References

• Chen CH, Wang SC, Tsou HH, et al. (2011). Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics 12:1397
   PubMed Web of Science ®Google Scholar
• Dai D, Tang J, Rose R, et al. (2001). Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299:825
   PubMed Web of Science ®Google Scholar
• Dai DP, Wang YH, Wang SH, et al. (2013). In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population. Acta Pharmacol Sin 34:1449–56
   PubMed Web of Science ®Google Scholar
• Drögemöller B, Plummer M, Korkie L, et al. (2013). Characterization of the genetic variation present in CYP3A4 in three South African populations. Front Genet 4:250–4
   PubMedGoogle Scholar
• Du J, Xing Q, Xu L, et al. (2006). Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 7:831–41
   PubMed Web of Science ®Google Scholar
• Dusman RE, Stanton MS, Miles WM, et al. (1990). Clinical features of amiodarone-induced pulmonary toxicity. Circulation 82:51–9
   PubMed Web of Science ®Google Scholar
• Eiselt R, Domanski TL, Zibat A, et al. (2001). Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447–58
   PubMedGoogle Scholar
• Evans WE, Relling MV. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487
   PubMed Web of Science ®Google Scholar
• Fumihiro Sata MD, Andrea Sapone MD, Elizondo G, et al. (2000). CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48
   PubMed Web of Science ®Google Scholar
• Ghovanloo MR, Abdelsayed M, Ruben PC. (2016). Effects of amiodarone and N-desethylamiodarone on cardiac voltage-gated sodium channels. Front Pharmacol 7:39
   PubMed Web of Science ®Google Scholar
• Gill J, Heel RC, Fitton A. (1992). Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 43:69
   PubMed Web of Science ®Google Scholar
• Haffajee CI, Love JC, Canada AT, et al. (1983). Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrythmias. Circulation 67:1347–55
   PubMed Web of Science ®Google Scholar
• Herrlin K, Yasui-Furukori N, Tybring G, et al. (2003). Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 56:415–21
   PubMed Web of Science ®Google Scholar
• Hsieh KP, Lin YY, Cheng CL, et al. (2001). Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29:268
   PubMed Web of Science ®Google Scholar
• Hu GX, Dai DP, Wang H, et al. (2017). Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population. Pharmacogenomics 18:369–79
   PubMed Web of Science ®Google Scholar
• Kamiya K, Nishiyama A, Yasui K, et al. (2001). Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation 103:1317
   PubMed Web of Science ®Google Scholar
• Kang YS, Park SY, Yim CH, et al. (2009). The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 85:312–18
   PubMed Web of Science ®Google Scholar
• Lamba JK, Lin YS, Thummel K, et al. (2002). Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121–32
   PubMedGoogle Scholar
• Li AP, Kaminski DL, Rasmussen A. (1995). Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1–8
   PubMed Web of Science ®Google Scholar
• Library WP. (2011). WHO Model List of Essential Medicines. Geneva, Switzerland: WHO
   Google Scholar
• Listed N. (1997). Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone trials meta-analysis investigators. Lancet 350:1417
   PubMed Web of Science ®Google Scholar
• Liu CH, Peck K, Huang JD, et al. (2005). Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics 6:731
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Nakamura K, Y, Guengerich F, et al. (2008). Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone. Drug Metab Dispos 36:2287
   PubMed Web of Science ®Google Scholar
• Nicolas JM, Espie P, Molimard M. (2009). Gender and interindividual variability in pharmacokinetics. Drug Metab Rev 41:408–21
   PubMed Web of Science ®Google Scholar
• Ohyama K, Nakajima M, Nakamura S, et al. (2000). A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 28:1303–10
   PubMed Web of Science ®Google Scholar
• Ozdemir V, Kalow W, Tang BK, et al. (2000). Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373
   PubMedGoogle Scholar
• Rankin S, Elder DH, Ogston S, et al. (2017). Population-level incidence and monitoring of adverse drug reactions with long-term amiodarone therapy. Cardiovasc Ther 35:e12258
   Web of Science ®Google Scholar
• Rendic S. (2002). Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83–448
   PubMed Web of Science ®Google Scholar
• Singh BN. (1998). Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol 81:3D
   PubMed Web of Science ®Google Scholar
• Trivier JM, Libersa C, Belloc C, Lhermitte M. (1993). Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report). Life Sci 52:PL91
   PubMed Web of Science ®Google Scholar
• Werk AN, Lefeldt S, Bruckmueller H, et al. (2014). CORRIGENDUM: identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. Clin Pharmacol Ther 96:416
   PubMed Web of Science ®Google Scholar
• Westlind-Johnsson A, Robert Hermann MD, Md AHM, et al. (2006). Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol Ther 79:339
   PubMed Web of Science ®Google Scholar
• Zanger UM, Turpeinen M, Klein K, Schwab M. (2008). Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093–108
   PubMed Web of Science ®Google Scholar
• Zhou HH, Liu ZQ. (2005). Ethnic differences in drug metabolism. Clin Chem Lab Med 38:899–903
   Web of Science ®Google Scholar
• Zhou Q, Yu X, Shu C, et al. (2011). Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet 56:415–22
   PubMed Web of Science ®Google Scholar
• Zhou SF. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310
   PubMed Web of Science ®Google Scholar
• Zipes DP, Prystowsky EN, Heger JJ. (1984). Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. J Am Coll Cardiol 3:1059–71
   PubMed Web of Science ®Google Scholar